Hydroxychloroquine for the Prevention of Cardiovascular Events in Myocardial Infarction Patients - a Safety Pilot Trial

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 125 participants.

Also called NCT02648464

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 125 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02648464
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Finland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02648464. Randomized; triple masking; primary purpose treatment. Start 2016-02-01 (actual); primary completion 2019-12-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Hydroxychloroquine for the Prevention of Cardiovascular Events in Myocardial Infarction Patients - a Safety Pilot Trial
Acronym
OXI
Condition
Acute Coronary Syndrome
Condition
Inflammation
Condition
Hydroxychloroquine
Condition
Antirheumatic Agents
Condition
Cardiovascular Diseases
Intervention (Drug)
Hydroxychloroquine
Intervention (Drug)
Placebo
Lead sponsor
Helsinki University Central Hospital (class: other)
Collaborator
Finnish Foundation for Cardiovascular Research (class: other)
Collaborator
Orion Corporation, Orion Pharma (class: industry)
Collaborator
Aarne Koskelo Foundation (class: other)
Collaborator
Finnish Cultural Foundation (class: other)

Record details

Record id
cardio:ct-nct02648464
Content hash
997f5c778ff38602658351a15f0b0fee024e38b4ee86ef28bf2f5e9bfeb911e3